Suchergebnisse - "Devos, Timothy"

PubPharm (102)

1

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial

enthalten in: Leukemia & lymphoma | 2024

von Gupta, V. | Oh, S. | Devos, T. | +14

2

CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

enthalten in: Haematologica | 2024

von Vermeersch, G. | Proost, P. | Struyf, S. | +2

3

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

enthalten in: EJHaem | 2024

von Oh, S. | Verstovsek, S. | Gupta, V. | +15

4

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

enthalten in: Haematologica | 2024

von Mesa, R. | Verstovsek, S. | Platzbecker, U. | +21

5

Predictors for improvement in patient-reported outcomes : post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria

enthalten in: Annals of hematology | 2024

von Schrezenmeier, H. | Kulasekararaj, A. | Mitchell, L. | +10

6

Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea : European observational study

enthalten in: European Journal of Haematology | 2024

von Theocharides, A. | Gisslinger, H. | De Stefano, V. | +15

7

Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea : European observational study

enthalten in: European journal of haematology | 2024

von Theocharides, A. | Gisslinger, H. | De Stefano, V. | +15

8

Exploring the relationship between anellovirus load and clinical variables in hospitalized COVID-19 patients : Implications for immune activation and inflammation

enthalten in: IJID regions | 2023

von Thijssen, M. | Devos, T. | Meyfroidt, G. | +2

9

Germline heterozygous SH2B3-mutations and (idiopathic) erythrocytosis : Detection of a previously undescribed mutation

enthalten in: EJHaem | 2023

von Vermeersch, G. | Devos, T. | Devos, H. | +3

10

MANIFEST : Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Mascarenhas, J. | Kremyanskaya, M. | Patriarca, A. | +21

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]